Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield NM colorectal screening Cov…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - New MexicoPolicy RPLAB071

    Colorectal Cancer Screening

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB071 alerts

    Get alerted when Policy RPLAB071 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines BCBSNM laboratory management reimbursement criteria for colorectal cancer screening tests and which screening modalities are reimbursable or excluded for asymptomatic individuals, affecting providers submitting claims to Blue Cross Blue Shield of New Mexico.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyColorectal Cancer Screening
    Policy CodePolicy RPLAB071
    Change TypeCode list updatesprior coverage revisions clarified
    Effective DateSep 4, 2026
    Last ReviewAug 8, 2025
    Next Review Date
    Key ActionSubmit claims with accurate supporting documentation and HIPAA‑approved code combinations; claims are subject to review.
    SourceLink
    POLICY UPDATE CHANGES

    Added code 87626 and removed code 0500T in the 05/15/2026 update.

    Previously (08/08/2025) reimbursement information was updated to add Cologuard Plus as reimbursable once every 3 years and to state cell-free DNA techniques (e.g., Guardant Shield) are not reimbursable.

    Reimbursement Information unchanged in the 05/15/2026 update; document updated with literature review and minor code list changes.

    45-75

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    age range where annual FIT/gFOBT screening may be reimbursable
    3 yrsinterval for reimbursable FIT-DNA
    Not reimb.methylated Septin 9 (ColoVantage)
    Over 75average-risk asymptomatic screening
    3 exclusionsnon-reimbursable screening techniques

    Coverage Criteria for Colorectal Cancer Screening

    Primary screening coverage

    Covered when ALL of the following are met:

    Individual is asymptomatic (no signs or symptoms suggestive of colorectal cancer).
    Individual age is between 45 and 75 years inclusive (average risk).45-75 years

    ALL of the following

    • ONE of

      • Fecal immunochemical test (FIT) — preferred; may be reimbursable if performed annually.
      • Guaiac fecal occult blood test (gFOBT); may be reimbursable if performed annually.

    Policy applies to asymptomatic, average-risk individuals; providers should confirm member eligibility and plan/contract terms.

    FIT-DNA coverage

    Covered when ALL of the following are met:

    Individual is asymptomatic (average risk).
    Individual age is between 45 and 75 years inclusive (average risk).45-75 years
    Test performed is a multitarget stool DNA test (FIT-DNA), e.g., Cologuard or Cologuard Plus.
    Interval: once every 3 years for FIT-DNA.
    Coverage status: FIT-DNA may be reimbursable when the above criteria are met.

    Non-reimbursable tests

    The following screening tests or techniques are not reimbursable for average-risk asymptomatic screening:

    ONE of

    • Methylated Septin 9 (ColoVantage) — not reimbursable.
    • Screening for anal cytologic abnormalities (anal pap smear) — not reimbursable.
    • Screening for anal HPV infection — not reimbursable.
    • Screening using cell-free DNA techniques (e.g., Guardant Shield) — not reimbursable.

    Inclusion of a procedure code in the code list does not by itself guarantee coverage or reimbursement eligibility; see Procedure Codes section for examples of codes referenced in this policy.

    Age-based exclusion

    Screening is not reimbursable when the following age-based condition is met:

    Individual is average risk, asymptomatic, and older than 75 years (i.e., age > 75).> 75 years

    For average-risk asymptomatic individuals over 75 years of age, colorectal cancer screening is not reimbursable.

    Procedure Codes and Frequency

    Procedure codes mentionedCPT
    81327SEPT9 GEN PRMTR MTHYLTN ALYS
    81528ONCOLOGY COLORECTAL SCR
    82270OCCULT BLOOD FECES
    82274ASSAY TEST FOR BLOOD FECAL
    87624HPV HI-RISK TYP POOLED RSLT
    87625HPV TYPES 16 & 18 ONLY
    87626HPV SEP HI-RSK TYP&POOL RSLT
    88112CYTOPATH CELL ENHANCE TECH
    0464UONC CLRCT SCR QRTSA DNA MRK
    0537UONC CLRCT CA CFDNA >2500 DMR
    FIT-DNA frequency
    FIT-DNA screening intervalOnce every 3 years for Cologuard or Cologuard Plus
    Applicable populationAverage-risk, asymptomatic individuals aged 45–75 years
    Coverage stanceMay be reimbursable when used as colorectal cancer screening

    Claims Documentation and Billing Requirements

    Documentation Required

    Claims documentation and coding requirement

    Providers must submit accurate documentation of services performed and use valid HIPAA-approved code combinations when filing claims; claims are subject to code edit protocols, claim review, and applicable plan/contract terms. Upon request, providers should be prepared to submit any additional documentation to support the claim.

    • Submit claims using valid code combinations from HIPAA‑approved code sets (CPT, HCPCS, ICD-10, etc.).
    • Ensure coding follows industry standard guidelines (Uniform Billing, AMA CPT guidance, CMS NCCI edits and policy manual).
    • Be prepared to provide additional documentation upon request for claim review and code edit resolution.

    Test Definitions and Notes

    fecal immunochemical test
    Test nameFecal immunochemical test (FIT)
    Preferred screeningPreferred option for annual colorectal cancer screening in average-risk, asymptomatic individuals aged 45–75
    IntervalAnnual when used for screening in eligible individuals
    guaiac fecal occult blood test
    Test nameGuaiac fecal occult blood test (gFOBT)
    Use for screeningMay be reimbursable as an annual screening option for average-risk, asymptomatic individuals aged 45–75
    Interval
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyColorectal Cancer Screening
    Policy CodePolicy RPLAB071
    Change TypeCode list updatesprior coverage revisions clarified
    Effective DateSep 4, 2026
    Last ReviewAug 8, 2025
    Next Review Date
    Key ActionSubmit claims with accurate supporting documentation and HIPAA‑approved code combinations; claims are subject to review.
    SourceLink
    On This Page
    Coverage Criteria for Colorectal Cancer ScreeningProcedure Codes and FrequencyClaims Documentation and Billing RequirementsTest Definitions and Notes
    Annual when used for screening in eligible individuals
    multitarget stool DNA test (e.g., Cologuard, Cologuard Plus)
    Test nameMultitarget stool DNA test (FIT-DNA) — e.g., Cologuard, Cologuard Plus
    Coverage stanceMay be reimbursable for colorectal cancer screening in average-risk, asymptomatic individuals aged 45–75
    Recommended intervalOnce every 3 years
    ColoVantage (blood-based methylation assay) — not reimbursable
    Test nameColoVantage (methylated Septin 9)
    Coverage stanceNot reimbursable for colorectal cancer screening
    NotesListed explicitly among techniques not reimbursable for average‑risk asymptomatic screening
    blood-based cfDNA screening tests (e.g., Guardant Shield) — not reimbursable
    Test classBlood-based cell‑free DNA (cfDNA) screening tests (e.g., Guardant Shield)
    Coverage stanceNot reimbursable for colorectal cancer screening
    ExamplesCell-free DNA techniques are listed among non-reimbursable screening techniques in the policy